search

Active clinical trials for "Lupus Nephritis"

Results 31-40 of 206

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis...

Lupus Nephritis

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with active lupus nephritis (LN)

Recruiting22 enrollment criteria

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Lupus Nephritis

Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).

Recruiting25 enrollment criteria

The Influence of Ketogenic Diet on Lupus Nephritis Patients' Immunity

Systemic Lupus ErythematosusKetogenic Dieting

The study investigates the dietary habits in relation to low doses of omega-3 fatty acids in subcutaneous adipose tissue, disease activity and atherosclerosis. The low intake of omega-3 and high intake of carbohydrate among patients with SLE appear to be associated with worse disease activity, adverse serum lipids and plaque presence.Three-month-old mice received an injection of pristane or saline solution and were fed with different experimental diets: sunflower oil diet or extra virgin olive oil (EVOO) diet. After 24 weeks, mice were sacrificed, spleens were collected and kidneys were removed for immunoinflammatory detections. The study have demonstrated that EVOO diet significantly reduced renal damage and decreased cytokine: TNF-α, IL-6, IL-10 and IL-17 production.The ketogenic diet utilizes a high fat, adequate protein, low carbohydrate diet that control type of food and exchange. The aim of the present study that ketogenic diet treated in SLE patients may decrease overactive immunity and associated inflammatory markers.

Recruiting6 enrollment criteria

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Refractory Systemic Lupus ErythematosusLupus Nephritis1 more

Investigator-initiated, single-arm, open-label, single dose clinical study to evaluate the safety and preliminary efficacy of CNCT19 in treatment of patients with refractory systemic lupus erythematosus(SLE) presented with active lupus nephritis or active immune thrombocytopenia.

Enrolling by invitation24 enrollment criteria

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Lupus Nephritis

The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis

Active11 enrollment criteria

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative...

Lupus ErythematosusLupus Nephritis

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis

Active21 enrollment criteria

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

IgA NephropathyLupus Nephritis3 more

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

Active19 enrollment criteria

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class...

Lupus Nephritis

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

Active12 enrollment criteria

Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Lupus Nephritis

Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus and had a diagnosis of systemic lupus erythematosus, and had active renal disease as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug.

Active2 enrollment criteria

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants...

Lupus Nephritis

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

Active17 enrollment criteria
1...345...21

Need Help? Contact our team!


We'll reach out to this number within 24 hrs